428 related articles for article (PubMed ID: 21519835)
1. Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea.
Jang G; Lee SS; Ahn JH; Jung KH; Lee H; Gong G; Kim HH; Ahn SD; Son BH; Ahn SH; Kim SB
Breast Cancer Res Treat; 2011 Jul; 128(1):171-7. PubMed ID: 21519835
[TBL] [Abstract][Full Text] [Related]
2. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype.
Arvold ND; Oh KS; Niemierko A; Taghian AG; Lin NU; Abi-Raad RF; Sreedhara M; Harris JR; Alexander BM
Breast Cancer Res Treat; 2012 Nov; 136(1):153-60. PubMed ID: 22968656
[TBL] [Abstract][Full Text] [Related]
3. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.
Heitz F; Harter P; Lueck HJ; Fissler-Eckhoff A; Lorenz-Salehi F; Scheil-Bertram S; Traut A; du Bois A
Eur J Cancer; 2009 Nov; 45(16):2792-8. PubMed ID: 19643597
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T
Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases.
NiwiĆska A; Murawska M; Pogoda K
Cancer; 2010 Sep; 116(18):4238-47. PubMed ID: 20549816
[TBL] [Abstract][Full Text] [Related]
6. Impact of triple-negative phenotype on prognosis of patients with breast cancer brain metastases.
Xu Z; Schlesinger D; Toulmin S; Rich T; Sheehan J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):612-8. PubMed ID: 22436795
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival.
Ishihara M; Mukai H; Nagai S; Onozawa M; Nihei K; Shimada T; Wada N
Oncology; 2013; 84(3):135-40. PubMed ID: 23235554
[TBL] [Abstract][Full Text] [Related]
8. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
9. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance imaging features in triple-negative breast cancer: comparison with luminal and HER2-overexpressing tumors.
Costantini M; Belli P; Distefano D; Bufi E; Matteo MD; Rinaldi P; Giuliani M; Petrone G; Magno S; Bonomo L
Clin Breast Cancer; 2012 Oct; 12(5):331-9. PubMed ID: 23040001
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
Breast; 2006 Apr; 15(2):219-25. PubMed ID: 16026983
[TBL] [Abstract][Full Text] [Related]
12. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathologic features and prognosis of triple negative breast cancer].
Zhou T; Yang L; Ma GM; Li CX; Bai Y; Zhao JA; Wang XL; Geng CZ
Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(32):2261-4. PubMed ID: 20095338
[TBL] [Abstract][Full Text] [Related]
14. Brain metastases in breast cancer: prognostic factors and management.
Lee SS; Ahn JH; Kim MK; Sym SJ; Gong G; Ahn SD; Kim SB; Kim WK
Breast Cancer Res Treat; 2008 Oct; 111(3):523-30. PubMed ID: 17990100
[TBL] [Abstract][Full Text] [Related]
15. Patterns of skin and soft tissue metastases from breast cancer according to subtypes: relationship between EGFR overexpression and skin manifestations.
Kong JH; Park YH; Kim JA; Kim JH; Yun J; Sun JM; Won YW; Lee S; Kim ST; Cho EY; Ahn JS; Im YH
Oncology; 2011; 81(1):55-62. PubMed ID: 21934337
[TBL] [Abstract][Full Text] [Related]
16. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
[TBL] [Abstract][Full Text] [Related]
17. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes and breast cancer subtypes in patients with brain metastases.
Kwon HC; Oh SY; Kim SH; Lee S; Kwon KA; Choi YJ; Cho GJ; Kim YS; Lee M; Lee JH; Kim DC; Lee HS; Cho SH; Kim HJ
Onkologie; 2010; 33(4):146-52. PubMed ID: 20389140
[TBL] [Abstract][Full Text] [Related]
19. Gamma Knife radiosurgery for brain metastases from primary breast cancer.
Kased N; Binder DK; McDermott MW; Nakamura JL; Huang K; Berger MS; Wara WM; Sneed PK
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1132-40. PubMed ID: 19345514
[TBL] [Abstract][Full Text] [Related]
20. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.
Niikura N; Hayashi N; Masuda N; Takashima S; Nakamura R; Watanabe K; Kanbayashi C; Ishida M; Hozumi Y; Tsuneizumi M; Kondo N; Naito Y; Honda Y; Matsui A; Fujisawa T; Oshitanai R; Yasojima H; Tokuda Y; Saji S; Iwata H
Breast Cancer Res Treat; 2014 Aug; 147(1):103-12. PubMed ID: 25106661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]